Alexandra Stefanovic, MD

Associate Professor of Medicine
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address alexandra.stefanovic@duke.edu

I am convinced that caring for patients with malignant hematologic diseases requires not only up-to-date medical knowledge, but also an understanding of the individual patient's needs and circumstances. I encourage patients to take an active role in their treatment and recovery and I work with them to develop an individualized treatment plan that includes the most advanced therapies available today. My practice focuses primarily on disorders of the lymphatic system (Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia). As an integral part of my clinical activities, I am dedicated to teaching young physicians at all levels of training and educating the next generation of hematologists.

Education and Training

  • Fellowship in Hematology/Oncology, Jackson Memorial Hospital, Miami, Florida, 2005 - 2008
  • Internal Medicine Residency, Western Pennsylvania Hospital, 2002 - 2005
  • M.D., University of Cologne (Germany, 1999

Publications

Lee, J. W., L. R. Prosnitz, A. Stefanovic, and C. R. Kelsey. “Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?.” Advances in Radiation Oncology, January 1, 2019. https://doi.org/10.1016/j.adro.2019.03.010.

Full Text

Kelly, Kevin R., Jonathan W. Friedberg, Steven I. Park, Kevin McDonagh, John Hayslip, Daniel Persky, Jia Ruan, et al. “Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma..” Clin Cancer Res 24, no. 24 (December 15, 2018): 6150–59. https://doi.org/10.1158/1078-0432.CCR-18-0286.

PMID
30082475
Full Text

Alderuccio, Juan Pablo, Alexandra Stefanovic, Daniel Dammrich, Jennifer R. Chapman, Francisco Vega, Gennaro Selvaggi, Andreas Tzakis, and Izidore S. Lossos. “Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy..” Leuk Lymphoma 59, no. 9 (September 2018): 2096–2104. https://doi.org/10.1080/10428194.2017.1413187.

PMID
29252057
Full Text

Dejman, Adriana, Seyed Navid Alavi, David B. Thomas, Alexandra Stefanovic, Arif Asif, and Ali Nayer. “The potential role of complements in cocaine-induced thrombotic microangiopathy..” Clin Kidney J 11, no. 1 (February 2018): 26–28. https://doi.org/10.1093/ckj/sfx061.

PMID
29423197
Full Text

Hosein, Peter J., Jose D. Sandoval-Sus, Deborah Goodman, Alexandra Gomez Arteaga, Isildinha Reis, James Hoffman, Alexandra Stefanovic, Joseph D. Rosenblatt, and Izidore S. Lossos. “Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma..” Am J Hematol 90, no. 6 (June 2015): E111–16. https://doi.org/10.1002/ajh.23996.

PMID
25737247
Full Text

Lossos, Izidore S., Jesus C. Fabregas, Tulay Koru-Sengul, Feng Miao, Deborah Goodman, Aldo N. Serafini, Peter J. Hosein, Alexandra Stefanovic, Joseph D. Rosenblatt, and James E. Hoffman. “Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma..” Leuk Lymphoma 56, no. 6 (June 2015): 1750–55. https://doi.org/10.3109/10428194.2014.975801.

PMID
25315074
Full Text

Fabregas, Jesus C., James E. Hoffman, Tulay Koru-Sengul, Miao Feng, Deborah Goodman, Aldo Serafini, Peter J. Hosein, Alexandra Stefanovic, Joseph D. Rosenblatt, and Izidore S. Lossos. “Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma.” In Blood, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Scholars@Duke

Deutsch, Yehuda E., Daniel J. Dammrich, Jesus C. Fabregas, Agustin Pirnentel, Alexandra Stefanovic, and James E. Hoffman. “Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.

Scholars@Duke

Kelly, Kevin R., Daniel O. Persky, Daruka Mahadevan, Thomas P. Miller, Soham D. Puvvada, Kevin McDonagh, John Hayslip, et al. “Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) plus Rituximab +/- Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas.” In Blood, Vol. 122. AMER SOC HEMATOLOGY, 2013.

Scholars@Duke

Sandoval-Sus, Jose D., Peter J. Hosein, Deborah Goodman, Alexandra Stefanovic, Joseph D. Rosenblatt, and Izidore S. Lossos. “Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.

Scholars@Duke

Pages